This sub-industry involves tests that identify genetic predispositions to diseases. The year 2024 sees growing adoption in personalized medicine and direct-to-consumer testing kits.
Cautious investment is suggested. There may be selective opportunities for turnaround specialists or those with high risk tolerance.